Peptide Profile

SLU-PP-332

Experimental ERR Agonist Exercise-Mimetic Compound

Research Only10 sources

Overview

Composition

Synthetic small molecule, not a peptide, described as a pan-estrogen-related receptor (ERR alpha/beta/gamma) agonist with strongest activity at ERR alpha

Mechanism of Action

Activates ERR-regulated transcriptional programs involved in oxidative metabolism, mitochondrial function, fatty-acid oxidation, and endurance-adaptation signaling

Primary Effects

In preclinical models, studied as an exercise mimetic that can induce aerobic-exercise-like gene expression, increase oxidative muscle features, improve endurance capacity, and affect metabolic-syndrome markers

Discovery & Background

Developed in academic medicinal chemistry programs studying synthetic agonists of estrogen-related receptors

Peer-reviewed reports in 2023 described SLU-PP-332 as inducing an ERR alpha-dependent acute aerobic exercise response and improving exercise capacity in mice; subsequent work explored metabolic syndrome, aging kidney, and analog optimization

No FDA approval; no established human therapeutic use

Research Overview

Evidence is preclinical.

01
Acts on ERR alpha/beta/gamma nuclear receptors, with reported highest potency at ERR alpha
02
In mouse studies, induced acute aerobic exercise gene programs in skeletal muscle
03
Enhanced exercise capacity and increased oxidative muscle adaptations in preclinical work
04
Other preclinical work explores metabolic syndrome and mitochondrial/inflammatory biology
05
No established human efficacy or safety profile exists
06
Related analog work is still preclinical and should not be extrapolated to human performance claims

Research-only small molecule; not approved for human use

Safety Considerations

Monitoring

Liver and kidney toxicity markers in preclinical studies
Cardiometabolic markers and body weight
Behavioral/activity changes
Sex-hormone and nuclear-receptor pathway concerns
Formulation and solvent toxicity

Side Effects

Unknown human safety

No established human adverse-event profile
Potential off-target nuclear receptor effects
Unknown long-term effects on metabolism, endocrine signaling, fertility, cardiovascular risk, or cancer biology

Formulation risk

Solvent/vehicle toxicity if improperly formulated
Purity and identity variability in research-chemical supply

Contraindications

Human use outside properly approved research
Pregnancy or breastfeeding
Known endocrine-sensitive disease without specialist oversight
Any attempt to replace exercise, nutrition, or evidence-based metabolic treatment